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Abstract: Glycosidase inhibitors have shown great potential as pharmacological chaperones for
lysosomal storage diseases. In light of this, a series of new cyclopentanoid β-galactosidase inhibitors
were prepared and their inhibitory and pharmacological chaperoning activities determined and
compared with those of lipophilic analogs of the potent β-d-galactosidase inhibitor 4-epi-isofagomine.
Structure-activity relationships were investigated by X-ray crystallography as well as by alterations
in the cyclopentane moiety such as deoxygenation and replacement by fluorine of a “strategic”
hydroxyl group. New compounds have revealed highly promising activities with a range of
β-galactosidase-compromised human cell lines and may serve as leads towards new pharmacological
chaperones for GM1-gangliosidosis and Morquio B disease.
Keywords: iminoalditol; 4-epi-isofagomine; carbasugar; aminocyclopentane; galactosidase inhibitor;
pharmacological chaperone; GM1-gangliosidosis
1. Introduction
Many glycoside hydrolases play important roles in various pathological processes,
including certain hereditary lysosomal disorders [1–3]. A group of about fifty of these metabolic
diseases arises from mutations in specific genes that lead to deficiencies in enzymes involved in
Molecules 2020, 25, 4025; doi:10.3390/molecules25174025 www.mdpi.com/journal/molecules
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the lysosomal degradation of glycolipids and glycans. Considerable efforts have been made to
develop novel therapeutics that may relieve the symptoms arising from the cellular accumulation
of the substrates of these deficient enzymes. These toxic accumulations, in turn, lead to irreversible
damage of nerve tissue and bones as well as various organs. For some of these lysosomal disorders,
enzyme replacement therapy [4,5], hematopoietic stem cell transplant [6,7], gene therapy [8,9], as well
as combination therapies [10] involving the administration of small molecules show considerable
promise. These small molecules may function by one of the following two mechanisms: Either by
substrate reduction therapy [11–13]—inhibiting upstream enzymes to reduce the initial production of
those metabolites whose degradation is impaired or as enzyme-stabilizing pharmacological chaperones
by assisting the folding and transport of mutant enzymes to the lysosome using sub-inhibitory
concentrations of active site-specific molecules (chaperone mediated therapy, CMT) [14–22].
Efforts of many groups have shown that imino sugar- as well as carba sugar-based glycomimetics
may be suitable as such therapeutic agents. Mutant proteins that cannot obtain/retain their functional
conformation are recognized as misfolded by the quality control machinery in the endoplasmic
reticulum and are eventually targeted for degradation. In CMT, the carba or imino sugars bind
to and stabilize mutant forms of enzymes (such as lysosomal β-glucosidase, β-galactosidase or
β-N-acetylhexosaminidase) in their functional folded conformations and thus facilitate their exit from
the endoplasmic reticulum and their subsequent transport to the lysosome.
Guiding contributions by various leaders in the field and recent reviews [23–26] have shown that
non-polar N-substituted iminoalditols and similarly functionalized structures bind better than their
more polar parent compounds. This is achieved through stronger interactions with the aglycon binding
site or with lipophilic pockets around the active site. In this context, N-butyl-1-deoxynojirimycin is
one of the best studied iminosugars, thus far [27]. Other researchers [28–31] have observed that large,
lipophilic substituents, for example, adamantyl capped spacer arms, greatly improve the interaction
between iminoalditol derivatives and the lysosomal β-glucosidase (Figure 1).
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Figure 1. Galactosidase inhibitors as potential therapeutic chaperones for mutation induced deficiencies
of lysosomal β-galactosidase.
GM1-Gangliosidosis and Morquio B disease are two manifestations of mutations on the GLB1
gene that encodes the vital lysosomal β-galactosidase. This enzyme is responsible for removal of a
β-galactosyl residue from the non-reducing end of its substrate, converting gangliosides GM1 and GA1
into GM2 and GA2, respectively. Depending on the location of the mutation, the resulting lysosomal
storage disorder is neurodegenerative (GM1-gangliosidosis) or bone-destructive (Morquio B) [32,33].
Three distinct structural types of β-galactosidase inhibitors have been investigated as potential
pharmacological chaperones for these two disorders. The first class is that of the epi-valienamines,
of which NOEV (N-octyl-epi-valienamine, 1, Figure 1) is a powerful β-galactosidase inhibitor [34]
and reportedly functions as a highly potent pharmacological chaperone for a wide range of
mutants of lysosomal β-galactosidase, even at sub-micromolar concentrations [35]. More recently,
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selected un-branched analogs lacking the hydroxymethyl group have been presented and their activities
with patients’ skin fibroblasts carrying the R201C mutation have been evaluated [36]. The second class of
potential chaperones are the hydroxylated piperidines exemplified by the deoxygalactonojirimycins, 2–4.
Through a variety of structural modifications, this scaffold has been transformed into a relatively small
number of derivative classes. Compounds 3–8 show several of the most active N-substituent-variants in
the literature, which have interesting properties as experimental pharmacological chaperones. [22,37–44].
C-5a-substituted derivatives of the known [45] isoiminosugar 4-epi-isofagomine (9), for example,
compounds 10–14 have recently been reported and shown to be potent β-galactosidase inhibitors
and superior pharmacological chaperones for selected GM1-gangliosidosis and Morquio B disease cell
lines [46–50].
The third class are the hydroxymethyl branched di- and trihydroxycyclopentylamines, which were
recently introduced as experimental pharmacological chaperones [51]. These compounds may be
regarded as products of ring contraction by formal homolytic extraction of the sugar ring oxygen and
bond formation between C-1 and C-5. The resulting carbacyclic scaffold maintains the stereochemical
information of the corresponding parent sugar or glycosylamine albeit with the characteristic
conformational features of five-membered rings. There are only three leading references presenting
such sugar analogues as proven d-galactosidase inhibitors [52–54]. Even more surprisingly, this family
of compounds reportedly harbours some of the most powerful inhibitors of β-galactosidases known
to date with inhibition constants in the sub-nanomolar range [52–54]. In particular, the β-d-galacto
configured cyclopentylamine bearing a 4-bromobenzyl moiety at the nitrogen (15, Figure 2), has been
found to excel in terms of inhibitory activity [52–54] and recently prepared [55] compounds 16 and 17
are powerful inhibitors of human lysosomal β-galactosidase and potent pharmacological chaperones
for the R201C mutant of this enzyme.
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Figure 2. Inhibitors 15–17.
In this study, which aims to extend the selection of chaperone structures useful for treating
GM1-gangliosidosis and Morquio B, we have investigated the effect of 4-epi-isofagomine derivatives
featuring dansylamino capped medium chain length aliphatic substituents. We have furthermore
explored the biochemical role of the OH group at C-2, which is a key functional group in natural
β-galactosidase substrates but is not present in the 4-epi-isofagomine inhibitors. This has consequences
both on the specific binding interactions formed and indirectly, on the basicity of the ring nitrogen
compared to the β-hydroxy substituted imino (2–8) or carba sugars such as 15, 16 and 17.
2. Results
2.1. Synthesis of 4-epi-Isofagomines
By analogy to the synthesis of (5aS)-dansylaminohexyl derivative 14 [46,47], (Figure 1) its
(5aR)-epimer 22 was prepared from known intermediate aldehyde 18 [56], by Wittig chain extension
employing triphenyl-(3-cyano)propyl phosphonium bromide to obtain nitrile 19. Subsequent terminal
modification, via primary amine 20 and protected 4-epi-isofagomine derivative 21 provided free
compound 22 featuring a dansyl capped aminohexyl chain at R-configured C-5a (Scheme 1).
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Scheme 1. Synthesis of inhibitor 22. a: Ph3P(CH2)3CN Br, LDA, THF(abs), N2, −78 ◦C to r.t., 66%;
b: Raney-Ni, H2, MeOH, 84%; c: dansyl chloride, NaHCO3, MeOH, 61%; d: HCl/MeOH, 74%.
2.2. Synthesis of Cyclopentylamines
Dansylaminohexyl substituted cyclopentane 17 was synthesized as described [55].
The corresponding deoxy derivative 31 was prepared from the recently reported [57] all-cis epimer 23
(Scheme 2). Activation of the free alcohol as a triflate (24) and treatment of the latter with sodium bromide
in DMF gave bromodeoxy derivative 25 with clean inversion of configuration. Simultaneous removal
of the bromo substituent and reductive isoxazolidine ring opening were achieved by use of Raney-Ni/H2
in MeOH, providing aminoalcohol 26 which, upon acid treatment, furnished free aminotriol 27 ready
for planned chemoselective N-alkylation [48,49,51], but, as a consequence of solubility problems, this
reaction was subsequently conducted with partially protected intermediate 26 (Scheme 2).
┑
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Scheme 2. Synthesis of 2-deoxy intermediate 26. a: (1) Tf2O, pyridine, CH2Cl2, 0 ◦C; (2) NaBr, DMF,
53% (2 steps); b: Raney-Ni, H2, MeOH, 66%; c: HCl/MeOH, 88%.
Isopropylidene-protected amine 26 was chemoselectively alkylated to provide nitrile 28 (Scheme 3)
which, in turn, was cleanly converted into primary amine 29 by catalytic hydrogenation over Raney-Ni.
Subsequent N-dansylation (30) and removal of the isopropylidene moiety gave deprotected deoxy
derivative 31 of parent compound 17 (Scheme 3).
┑
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Scheme 3. Synthesis of compound 31. a: Br(CH2)5CN, NaHCO3, DMF, 70 ◦C, 62%; b: Raney-Ni, H2,
MeOH, 78%; c: (1) dansyl chloride, Et3N, CH2Cl2-DMF (3:1); d: HCl/MeOH, 84% (2 steps).
In order to evaluate the influence of “polar deoxygenation” at C-2, the novel deoxyfluoro analogue
37 was synthesized by reaction of precursor 23 with DAST to furnish compound 32 and subsequent
structural elaboration via intermediates 33–36 by analogous methods to those described for derivative
31 (Scheme 4).
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Scheme 4. Synthesis of 2-deoxy-2-fluoro compound 37. a: DAST, pyridine, CH2Cl2, 0 ◦C, 82%; b: Pd/C,
H2, MeOH, 98%; c: HCl/MeOH, 92%; d: HCO(CH2)6NHCbz, NaCNBH3, AcOH, MeOH, 60%; e: Pd/C,
H2, MeOH; f: dansyl chloride, Et3N, CH3CN–H2O (5:1), 53%.
The structure of intermediate 33 was confirmed by X-ray analysis (Figure 3).
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Figure 3. Crystal structure of compound 33 (CCDC 2018297).
2.3. Inhibitory Activities
Results of screening of new isofagomine derivative 22 as well as cyclopentanes 31 and 37 in
comparison with their previously reported respective relatives 11, 16 and 17 as well as pyranoid
carbasugar derivative 1 employing a panel of representative d-galactosidases and d-glucosidases
are collected in Table 1. Inhibition constants across the series tend to favor the binding of the
piperidine structure 22, with all β-glycosidases tested being inhibited in the low to sub-nanomolar
range. Close behind this in affinity comes the new dansylated cyclopentanoid inhibitor 17. Most of
the β-glycosidases are inhibited in the low, but not sub-, nanomolar range, with the exceptions
being the human lysosomal β-galactosidase (from CAZY [58,59] family GH35) and human lysosomal
β-glucocerebrosidase.
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Table 1. Ki-values [µM] of compounds with Abg = β-glucosidase/β-galactosidase from Agrobacterium sp.; E. coli = lac Z β-galactosidase from E. coli; Bovine liver =
β-galactosidase from bovine liver; Fabrazyme = commercial recombinant lysosomal α-galactosidase; S. cer. = α-glucosidase from S. cerevisiae; GCase = recombinant
human lysosomal β-glucocerebrosidase; β-Gal. human lys. = human lysosomal acid β-galactosidase; IC50 [µM] with β-Gal (human lysosomal); n.i. = no inhibition,
with Ki > 1 mM.
Enzyme
(GH Family)
Compounds
valuesや》ょM『やofやcompoundsやwithや“bgや└やぽ glucosidaseのぽ ぽ ╉や”ovineやliverや└やぽ
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14 (ref.46) 
ぽ ) 
ぽ
ぽ-
〉ぼ
〉ぼ
ぽ  
ぽ
[46,47]
valuesや》ょM『やofやcompoundsやwithや“bgや└やぽ glucosidaseのぽ ぽ ╉や”ovineやliverや└やぽ
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16
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37 
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1
Abg (β-Glc/Gal)
(GH1) 0.0003 0.0175 0.0010 0.0012 0.0035 0.077 7.7
E. coli (β-Gal)
(GH2) 0.0004 0.0021 0.0132 0.0101 0.0041 5.2 2.8
Bovine liver
(β-Gal)
(GH35)
0.0005 0.0014 0.1167 0.0053 0.102 0.137 0.87 [16]
Fabrazyme (α-Gal)
(GH27) n.i. n.i. n.i. 238.1 n.i. n.i. n.i.
S. cer. (α-Glc)
(GH13) n.i. n.i. n.i. n.i. n.i. 22.5 n.i.
GCase (β-Glc)
(GH30) 0.003 1.2 0.0639 0.0193 22.6 3.0 83
β-Gal human
lys. (GH35); IC50
0.094 0.38 0.42 0.40 82.5 34.9 0.51
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Inspection of the structures of complexes with a bacterial GH35 β-galactosidase (see below) reveals
an exquisite set of interactions between the active site residues and the polar groups of 22, including a
potentially electrostatic interaction between the catalytic nucleophile, Glu349, and the ring nitrogen.
Most of these interactions are essentially replicated in the complex with 17. Importantly, in the absence
of an endocyclic nitrogen partner, Glu 349 now forms a strong interaction with the hydroxyl group at
C-2, the secondary carbon adjacent to the alkylamine substituent on the ring. The importance of this
interaction is clearly seen in comparing the Ki value of the GH35 bovine β-galactosidase with 17 and
31. These inhibitors differ only in the presence of the hydroxyl group at that position, and indeed 31
binds some 20 fold less tightly, corresponding to an approximate 2 kcal/mol difference. An even bigger
200 fold affinity difference is seen for the human lysosomal β-galactosidase (GH35), implying crucial
interactions of this particular hydroxyl group with GH35 enzymes. The substitution of a fluorine at
that position rather than a hydroxyl group has similarly negative consequences. In the cases of both
the mammalian β-galactosidases, the fluorine analogue binds in similar ranges as the parent with a
hydrogen at that position but more than 12 times (bovine liver) to approx. 90 times (human lysosomal)
worse than the hydroxylated version, implying highly reduced stabilizing interaction at that position.
Binding to the GH1 and GH2 bacterial glycosidases is also considerably worse, by 64 and approx. 500
fold respectively, when compared to inhibitor 17. Since the (minimal) size difference of F vs. H is
unlikely to result in such significant changes, a destabilizing dipolar interaction of the C-F-system
with a dipole in the active site is the most probable root cause. Indeed the crystal structure reveals
that this could arise from unfavorable interactions of the fluorine atom with the carboxylate group of
Glu349, since no hydrogen bond like that seen with the hydroxyl of 17, can be formed. The strongly
electron-withdrawing effect of the fluorine atom may also cause a significant reduction of the amine’s
basicity (when compared to parent compound 17 and the more basic deoxy derivative 31), which in
turn could affect binding.
2.4. Inhibitor Binding in Crystal Structures of a Model β-Galactosidase from Cellvibrio Japonicus
Based on X-ray crystallographic studies of compounds 1, 14, 16, 17 as well as 22 and 31 in complex
with Cellvibrio japonicus β-galactosidase (CjGH35), a tractable bacterial model which shows around 27%
sequence identity with the human enzyme, notably conserved active centers, intensities of inhibition
and chaperoning properties, may be partially rationalized (Figure 4).
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Figure 4. Overlay of DGJ in structures with human β-gal and CjGH35. Side-chains, and main-chain
for Ala128 in human β-gal, forming hydrogen bonds (shown as dashed lines) with DGJ in 3THD.pdb
and 4D1J.pdb respectively are shown, as well as the catalytic acid/base residues (Glu188 and 205
respectively). NB Active sites are from molecules A, but Asp550 is from molecule C in CjGH35. C atoms
are colored lilac for human β-gal and lawn green for CjGH35 (with ligand C atoms in orchid and
green respectively). The label for Asn135 for CjGH35 is omitted for clarity. Figure was made using
CCP4mg [60].
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Figure 4 shows an overlay of the ligand molecules in the X-ray structures for human lysosomal
β-d-galactosidase (human β-gal) and CjGH35 complexed with 1-deoxygalactonojirimycin (3THD.pdb
and 4D1J.pdb respectively). The catalytic residues lie in a similar position in the two structures,
with the nucleophiles (Glu268 and Glu349) accepting a hydrogen bond from the ligand 2-OH group.
Both enzymes also feature an asparagine adjacent to the acid/base (at 187 and 204 respectively),
which interacts with the 2-OH via its ND2 group, and a carboxyl group which tethers the 4-OH and
6-OH groups (in human β-gal this is from Glu129, which is on a loop in the TIM barrel domain,
whereas in the CjGH35 crystal this is provided by Asp550 in the C-terminal domain of an adjacent
protein chain). For the inhibitors studied here, the ligand sugar moieties have clear density in all the
active sites and overlay with ring C atoms 2 to 5 in similar positions (Figure 5). Figure 5 displays
hydrogen bonding interactions between amino acid residues in the active site of CjGH35 and ligands 1,
14, 16, 17, 22 as well as 31 respectively. The side-chains of Asn135 (which forms hydrogen bonds of 3.0
Å from ND2 to C4-OH) and of Asp550E have been omitted for clarity.
ぽ
 
Compound 1. 
Compound 14. 
Compound 16. 
Figure 5. Cont.
Molecules 2020, 25, 4025 9 of 25
 
Compound 17. 
 
Compound 22. 
Compound 31. 
Figure 5. Illustration of ligand complexes with CjGH35, showing hydrogen-bonding interactions (as
dashed lines) between the modelled ligand atoms and protein side-chains, and ligand electron density
(calculated as omit difference density maps contoured at 2 rmsd). For 17, side-chains involved in
aromatic interactions within 3.8 Å of the NH-dansyl group are also shown. The side-chain of Asn135 is
omitted from the interactions figure for 17, and the electron density pictures to aid clarity.
For all the C-1-substituents in 1, 16, 17 and 31, (an NH-octyl group in 1 and 16,
and NH-C6-NH-dansyl groups in 17 and 31), and the C-5a-substituted NH-C6-NH-dansyl groups in
14 and 22, there are very few interactions between the protein and substituted derivative moieties.
The NH-C6-NH-dansyl group was only able to be modelled for 17, and only at an occupancy of 0.5.
For molecules 14, 22 and 31 there is no electron density for the 5-(dimethylamino)naphthalene moiety.
The active site residues are similarly oriented in all of the structures, with slight differences for 31,
as mentioned below.
The most salient variation in hydrogen bonding occurs at the 2-OH group, which is present in
1, 16 and 17. The group is tethered by interactions with ND2 Asn204 (all 2.8–3.0 Å) and to both OE
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atoms of Glu349 (2.6–2.7 Å) Hydrogen bonding patterns for 16 and 17 are very similar, despite the
different groups bound at C-1, which are probably flexible and show few polar interactions with the
protein, and not surprisingly, the Ki values determined for these inhibitors with recombinant human
lysosomal β-Gal are very similar. Ligand 31 is identical to 17 apart from lacking a hydroxyl group
at C-2, the importance of which is reflected in a much poorer Ki value (200-fold worse for human
lysosomal β-galactosidase). There are two other differences in the ligand interactions of 31 (not only
from those seen for 17, but also from the other complexes studied here). Firstly, there is a hydrogen
bond from the C-3 hydroxyl to ND2 Asn204, in addition to the three hydrogen bonds to Asn67,
Lys134 and a water molecule (which is hydrogen bonded to OD1 Asn204 and OE1 Gln64). Secondly,
there is a shift in the position of Gln64, with the NE2 atom forming a hydrogen bond to O Ala348,
instead of the OE1 interacting with a water which is hydrogen bonded between O Thr65 and ND2
Asn67 (as seen in the other structures). These probably play a far lesser contribution to the weaker Ki
values than the absence of three potential hydrogen bonds from a C-2-OH group.
Another key ligand-protein interaction is displayed for compounds 1, 16, 17 and 31, which feature
hydrogen bonding interactions from their amine groups at ring position 1 to Glu205 (2.6–2.8 Å) and
with a water which is also hydrogen bonded to ND2 Asn135, and in the case of 1, to the C-4 hydroxyl
group. While there is no equivalent group for 14 and 22, the Glu205 side-chain is oriented similarly in
all of the structures despite the lack of hydrogen bonds with a C-2 hydroxyl group for 14 as well as 22
and 31. The position of Glu205 may be maintained by an additional hydrogen bond from its OE1 atom
to a water which is also hydrogen-bonded to OH Tyr209.
In contrast to the carbacyclic compounds, 14 and 22 have a nitrogen atom in position 1 of the
ring. The sugar conformation is close to “4C1” (=4CN) in both, and the N of the isofagomine moiety is
hydrogen bonded to Glu205 and Glu349, which may compensate for the lack of interactions from an
NH group at the start of the hydrocarbon chain seen for compounds 1, 16, 17 and 31. The absence
of a C-2-position hydroxyl group will increase the basicity of the N atom, allowing it to also form
electrostatic interactions with Glu349. In the structure with 22 the N atom points more steeply
downwards away from the plane of the ring forming a closer hydrogen bond with OE1 Glu349 than for
14 (2.5–2.6 Å for all of the molecules in the asymmetric unit, as opposed to 2.6–2.8 Å for 14). This may
contribute to the better inhibition observed for 22 than for 14 with all the galactosidases tested.
In 1, which is known to be a powerful β-galactosidase inhibitor, the sugar conformation is closer
to 4H3, probably because of the double bond between C-5 and C-5a, and reflecting that the C in ring
position 2 is not attracted downwards towards the catalytic Glu residues in the same way as for the
isofagomine N atom in 14 and 22.
Overlays of the compared ligand structures and active sites are shown in Figure 6.
2.5. Chaperoning Activities
Chaperoning activities of compounds with GM1-gangliosidosis and Morquio B related cell lines
are outlined in Figures 7 and 8. Cells with the R201C mutant of β-galactosidase which is related to
juvenile GM1-gangliosidosis and has previously been shown to be amenable to chaperone 1 reacted
very positively to isofagomine derivatives 11, 14 and 22 as well as to cyclopentanoid ligands 16 and 17.
The corresponding deoxy derivative 31 exhibited distinctly reduced chaperoning activity and was only
trailed by deoxyfluoro analog 37. Incubation of the cells with compounds 31 and 37, respectively, up to
10 µM had no notable influence on β-galactosidase activity and cell viability. Higher concentrations
of these inhibitors led to decreased enzyme activity and to a complete arrest of cell growth over the
incubation time. Concentrations of more than 100 µM resulted in dramatic loss of both, β-galactosidase
activity as well as cell viability.
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Figure 6. Overlay of inhibitors.
With R201H/H281Y (adult GM1-gangliosidosis), both structural types, 11 as well as 17, show β-gal
activity increases of 6- to 7-fold at 0.1 µM and 9- to 10-fold at 1 µM with slight advantages for
isofagomine derivative 11. For comparison, the maximum effect of carbasugar 1 (6.8-fold increase) is
clearly shifted to higher chaperone concentrations of 10–25 µM (Figure 7).
With C230R/C230R (late infantile GM1-gangliosidosis), chaperoning maxima were reached at 1 µM
with 4-epi-isofagomine 11 (12-fold) and between 1 and 10 µM (7-fold) with carbacycle 17 (NOEV, 1,
6.4-fold). The Morquio B/GM1-gangliosidosis mutation R201H/S149F exhibits comparable sensitivities
to all three chaperones screened, with small advantage for NOEV (1, ≥10-fold), followed by 11 (9.5-fold)
and 17 (9-fold). Interestingly, with Y333H/Y333H (juvenile GM1-gangliosidosis), carbacycle 17 is
the most potent chaperone with a maximum activity of nearly 9-fold at 10 µM, followed by NOEV
(1, nearly 8-fold at 25 µM) and 11 (5-fold at 25 µM). None of the three chaperones probed showed
any chaperone activity with Y270D/Y270D and G438E/G438E, respectively. The compounds had no
inhibitory effects on human lysosomal hexosaminidase in the concentration range probed (Figure 8).
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3. Discussion
Two types of structurally very different but similarly potent β-galactosidase inhibitors,
the C-5-chain extended 4-epi-isofagomines (14 and 22) as well as d-galacto configured
aminohydroxymethyl-cyclopentane derivatives 17, 31 and 37 were investigated concerning their
properties as pharmacological chaperones for selected GM1-gangliosidosis as well as Morquio B cell
lines. To gain more in-depth insights into structural requirements for good inhibition and chaperoning,
an important hydroxyl group in the cyclopentanoid series was substituted. Removal of this secondary
alcohol was expected to provide isofagomine-like improved activity through increase of the amine’s
basicity whereas its substitution with a fluorine atom was exploited to probe hydrogen bonding with
the amino acid residues in and around the active site.
New inhibitor 22 turned out to be highly potent and exhibited encouraging dose-dependent
chaperoning profiles with enzyme mutant R201C. For the cyclopentanoid chaperones, on the other
hand, OH-2 appears to be a vital feature for their activity as inhibitors and pharmacological chaperones,
since its absence and the concomitantly increased basicity of the adjacent amine apparently cannot
compensate for the reduced number of interactions with amino acid residues resulting from the
removal of this particularly crucial functional group.
Notably, despite indisputable biochemical evidence based on quite a few inhibitors
probed [41,46,47,55,61–64], the frequently observed synergistic inhibitory effect of the terminal dansyl
amide could not be correlated to additional specific binding events of this moiety to the protein as was
implied by the lack of electron density for this substituent in the bacterial model enzyme-inhibitor
complexes examined.
Furthermore, it is interesting to note that the five β-galactosidase mutants investigated (Figure 8)
exhibit distinctly different susceptibilities towards the three classes of chaperones screened. Whereas for
R201H/H281Y and, in particular, C230R/C230R the isoimino sugars (for example 11) are clearly the
most efficient chaperones across the entire concentration range probed, cyclopentane 17 shows clear
advantage over pyranoid carbasugar 1 as well as piperidine 11 with Y333H/Y333H, and in the case of
R201H/S149F, carbasugar NOEV (1), turned out to be the most potent chaperone for this particular
mutant. Thus, for the development of effective pharmacological chaperones, the individual mutant
under scrutiny should be screened with a representative range of suitable ligand types for optimized
chaperoning efficacy.
4. Experimental
4.1. Synthetic Section
XRD data and NMR spectra for new compounds are all in the Supplementary Materials.
Optical rotations were measured at 20 ◦C on a Perkin Elmer 341 polarimeter (Perkin Elmer, Waltham,
MA, USA) at a wavelength of 589 nm and a path length of 10 cm. NMR spectra were recorded on a
Varian INOVA 500 (Varian, Palo Alto, CA, USA) operating at 499.82 MHz (1H), 470.3 MHz (19F) and at
125.894 MHz (13C) or on a Bruker (Billerica, MA, USA) Ultrashield spectrometer at 300.36 (1H) and
75.53 (13C) MHz, respectively. CDCl3 was employed for protected compounds and methanol-d4 or
D2O for unprotected inhibitors. Carbon and hydrogen numbering in NMR spectra was conducted in
analogy to carbohydrate nomenclature and clockwise, starting with the amino bearing carbon as C-1
(Numbering pattern for cyclopentanes shown in Figure 2). Chemical shifts are listed in delta employing
residual, non-deuterated solvent as the internal standard. Signals were assigned unambiguously
by COSY, HSQC as well as APT analysis. For the sake of simplicity and comparison, carbohydrate
numbering has been applied to the hydroxymethyl cyclopentane series throughout this work. This may
be accounted for by the fact that these compounds can be regarded “monosaccharide derivatives”
resulting from formal homolytic extrusion of the ring oxygen. Stereochemical features remain the same
as in the respective parent sugar. The signals of the aromatic groups are located in the expected regions
and are not listed explicitly. The signals of the protecting groups as well as of the N-substituents
Molecules 2020, 25, 4025 14 of 25
were found in the expected regions and are only listed explicitly when overlapping with important
spectral features of the respective compound. Due to stable rotameric populations of the N-Boc group,
signal splitting in the respective NMR spectra has been observed leading to somewhat poor resolution
of the 1H-NMR and 13C-NMR spectra. Signals of N-Boc protected compounds may be retarded or
show up as pairs. For crucial intermediate 33, the structure was confirmed by XRD structural analysis:
Suitable single crystals of compounds were immersed in silicone oil, mounted using a glass fiber and
frozen in the cold nitrogen stream (100 K). X-Ray diffraction data were collected at low temperature
on a Bruker Kappa APEX II diffractometer using Mo Ka radiation (l = 0.71073 Å) generated by an
INCOATEC micro-focus source. The data reduction and absorption correction was performed with the
Bruker SMART (Bruker AXS Inc., Madison, WI, USA) and Bruker SADABS (Bruker AXS Inc., Madison,
Wisconsin, USA), respectively. The structures were solved with SHELXT [65] by direct methods and
refined with SHELXL by least-square minimization against F2 using first isotropic and later anisotropic
thermal parameters for all non-hydrogen atoms. Hydrogen atoms were added to the structure models
on calculated positions using the riding model. The space group assignments and structural solutions
were evaluated using PLATON [66,67].
MALDI-TOF Mass Spectrometry was performed on a Micromass TofSpec 2E Time-of-Flight Mass
Spectrometer (Waters Corporation, Milford, MA, USA). Analytical TLC was performed on precoated
aluminum plates silica gel 60 F254 (E. Merck 5554, E. Merck, Darmstadt, Germany) and detected
with UV light (254 nm). For staining, a solution of vanillin (9 g) in a mixture of H2O (950 mL)/EtOH
(750 mL)/H2SO4 (120 mL) or ceric ammonium molybdate (100 g ammonium molybdate/8 g ceric sulfate
in 10% H2SO4 (1 L)) were employed followed by heating on a hotplate. For column chromatography,
silica gel 60 (230–400 mesh, E. Merck 9385) or silica gel 60 (Acros Organics, AC 24036, Thermo Fisher
Scientific Inc., Waltham, MA, USA) were used.
6-[(5aR)-(N-tert-Butyloxycarbonyl-3,4-O-isopropylidene-6-O-methoxymethylene-4-epi-
isofagomin-5a-yl)-hex-4-enoic nitrile (19)
A solution of freshly prepared LDA [by dropwise addition of 2.5 M n-BuLi (2.0 mL) in hexane to
diisopropyl amine (0.18 mL, 1.3 mmol, 20% solution in dry THF)] in dry THF was added dropwise at
−78 ◦C under an atmosphere of nitrogen to a suspension of triphenyl-(3-cyano)propylphosphonium
bromide (557 mg, 1.36 mmol). After stirring at −40◦C for 60 min, a solution of aldehyde 18 (ref. [46,47],
150 mg, 0.39 mmol, dissolved in 2 mL dry THF) was added dropwise. After having been stirred for 12 h,
the reaction mixture was diluted with CH2Cl2 and consecutively washed with HCl (6%) and saturated
NaHCO3. After drying over Na2SO4, the filtrate was concentrated under reduced pressure to provide
the crude product. Chromatographic purification (cyclohexane–EtOAc 20:1 to cyclohexane–EtOAc
10:1) afforded nitrile 19 (110 mg, 0.25 mmol, 66%) as a mixture of the E/Z-isomers. 1H NMR (300 MHz,
CD3OD): δ = 5.40 (bs, 2 H, H-2′, H-3′), 4.63–4.55 (m, 2 H, O-CH2-O-CH3), 4.47–3.80 (m, 4 H, H-2eq,
H-3, H-4, H-5a), 3.60 (m, 2 H, H-6a, H-6b), 3.33–3.28 (m, 3 H, O-CH2-O-CH3), 2.62 (m, 2 H, H-2ax,
H-1′a), 2.45–2.01 (m, 6 H, H-5, H-1′b, H-4′a, H-4′b, H-5′a, H-5′b), 1.47 (s, 3 H, C(CH3)2), 1.38 (s, 9 H,
N-CO-C(CH3)3), 1.27 (s, 3 H, C(CH3)2); 13C NMR (75.5 MHz, CD3OD): δ= 154.7, 154.4 (N-CO-C(CH3)3),
129.7–126.7 (C-2′, C-3′), 119.1, 119.0 (C-6′), 109.2, 109.2 (C(CH3)2), 96.6, 96.5 (O-CH2-O-CH3), 80.6,
79.9 (N-CO-C(CH3)3), 73.0, 72.9, 71.0, 70.4 (C-3, C-4), 66.3, 65.9 (C-6), 55.4, 55.3 (O-CH2-O-CH3), 50.5,
49.3 (C-5a), 40.2, 39.8, 39.3, 38.9 (C-2, C-5, C-4′), 29.7, 29.8, 28.7, 28.3, 25.9 (N-CO-C(CH3)3, C(CH3)2),
23.6, 23.3, 17.4 (C-1′, C-4′, C-5′). MS (MALDI): Calcd for [C22H36N2O6Na]+: m/z 447.2471 [M]+;
Found [M]+ 447.2468.
(5aR)-N-tert-Butyloxycarbonyl-5a-C-(6-amino)hexyl-3,4-O-isopropylidene-6-methoxymethylene-
4-epi-isofagomine (20)
A 10% solution of the nitrile 19 (110 mg, 0.25 mmol) in MeOH was stirred with Raney-Ni (moist
in H2O) under an atmosphere of H2 at ambient pressure for 60 min. After completed conversion of the
starting material, the catalyst was filtered off. Removal of the solvent, followed by purification on silica
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gel (CHCl3–MeOH 8:1 + 1 vol% NH4OH (25%)) provided amine 20 (92 mg, 0.21 mmol, 84%) as a yellow
syrup. [α]20D : −1.2 (c 2.6, MeOH);
1H NMR (300 MHz, CD3OD): δ = 4.66–4.63 (m, 2 H, O-CH2-O-CH3),
4.32 (m, 2 H, H-4, H-5a), 4.13–3.91 (m, 2 H, H-2eq, H-4), 3.39–3.35 (m, 3 H, O-CH2-O-CH3), 3.68 (m, 2 H,
H-6a, H-6b), 2.82 (t, 2 H, H-6′), 2.81 (m, 1 H, H-2ax), 2.32 (m, 1 H, H-5), 2.06 (m, 1 H, H-1′a), 1.69–1.16
(m, 24 H, H-1′b, H-2′, H-3′, H-4′, H-5′, C(CH3)3, N-CO-C(CH3)3). 13C NMR (75.5 MHz, CD3OD): δ =
156.7, 156.5 (N-CO-C(CH3)3), 110.5 (C(CH3)2), 97.8, 97.6 (O-CH2-O-CH3), 81.5, 81.3 (N-CO-C(CH3)3),
74.5, 72.2, 72.0 (C-3, C-4), 67.5, 67.3 (C-6), 55.7 (O-CH2-O-CH3), 52.2, 50.8 (C-5a), 41.9, 41.4, 41.1, 40.7,
39.9 (C-2, C-5, C-6′), 32.2–26.2 (C-1′, C-2′, C-3′, C-4′, C-5′, N-CO-C(CH3)3, C(CH3)2). MS (MALDI):
Calcd for [C22H42N2O6Na]+: m/z 453.2941 [M]+; Found [M]+ 453.2940.
(5aR)-N-tert-Butyloxycarbonyl-5a-C-(6-dansylamino)hexyl-3,4-O-isopropylidene-6-O-
methoxymethylene-4-epi-isofagomine (21)
To a suspension of amine 20 (92 mg, 0.21 mmol) and Na2CO3 (68 mg, 0.64 mmol) in 3 mL MeOH,
dansyl chloride (69 mg, 0.26 mmol) was added. After completed conversion of the starting material,
the reaction mixture was evaporated to dryness. Purification on silica gel (cyclohexane–EtOAc 15:1)
gave partially protected dansylamide 21 (86 mg, 0.13 mmol, 61%) as fluorescent wax. [α]20D : +0.7 (c 1.0,
CHCl3); 1H NMR (300 MHz, CDCl3): δ = 4.70–4.56 (m, 2 H, O-CH2-O-CH3), 4.26–3.81 (m, 4 H, H-2eq,
H-3, H-4, H-5a), 3.55 (m, 2 H, H-6a, H-6b), 3.41–3.32 (m, 3 H, O-CH2-O-CH3), 2.78 (m, 2 H, H-6′),
2.52 (m, 1 H, H-2ax), 2.18 (m, 1 H, H-5), 1.78 (m, 1 H, H-1′a), 1.46 (s, 3 H, (C(CH3)2), 1.43 (s, 9 H,
N-CO-C(CH3)3), 1.30 (s, 3 H, (C(CH3)2), 1.28–0.94 (m, 9 H, H-1′b, H-2′, H-3′, H-4′, H-5′). 13C NMR
(75.5 MHz, CDCl3): δ = 155.0, 154.8 (N-CO-C(CH3)3), 109.3 (C(CH3)2), 96.7, 96.6 (O-CH2-O-CH3),
80.0, 79.9 (N-CO-C(CH3)3), 73.2, 73.1, 71.1, 70.9 (C-3, C-4), 66.5, 66.1 (C-6), 55.5, 55.4 (O-CH2-O-CH3),
50.8, 49.5 (C-5a), 45.6 (dansyl), 43.5, 43.4 (C-6′), 40.1, 39.5, 38.8 (C-2, C-5), 29.8, 29.6 (C-1′), 28.8,
26.5 (C(CH3)2), 28.7, 28.6 (N-CO-C(CH3)3), 27.1–26.2 (C-2′, C-3′, C-4′, C-5′). MS (MALDI): Calcd for
[C34H53N3O8SNa]+: m/z 686.3451 [M]+; Found [M]+ 686.3450.
(5aR)-5a-C-(6-Dansylamino)hexyl-4-epi-isofagomine (22)
Compound 21 (86 mg, 0.13 mmol) was dissolved in MeOH (3 mL) and HCl (12 M) was added
dropwise to adjust pH 1. After completed removal of all protecting groups, the solvents were removed
under reduced pressure. Purification on silica gel (CHCl3–MeOH 8:1 + 1 vol% NH4OH (25%)) yielded
free compound 22 (46 mg, 0.096 mmol, 74%) as fluorescent wax. [α]20D : −19.1 (c 0.58, MeOH);
1H NMR
(300 MHz, CD3OD): δ = 3.85 (m, 3 H, H-3, H-4, H-6a), 3.70 (dd, 1 H, J6a,6b 11.8 Hz, J5,6b 4.5 Hz, H-6b),
3.21 (m, 1 H, H-5a), 3.12 (dd, 1 H, J2ax,2eq 12.3 Hz, J2eq,3 2.9 Hz, H-2eq), 3.07 (dd, 1 H, J2ax,3 2.3 Hz,
H-2ax), 3.07 (t, 2 H, H-6′), 2.01 (m, 1 H, H-5), 1.66 (m, 2 H, H-1′), 1.34–0.96 (m, 8 H, H-2′, H-3′, H-4′,
H-5′). 13C NMR (75.5 MHz, CD3OD): δ = 69.3 (C-4), 66.7 (C-3), 58.6 (C-5a), 57.4 (C-6), 45.8 (dansyl),
43.7 (C-6′), 42.3 (C-5), 30.4, 30.1, 29.6, 27.1, 26.5 (C-1′, C-2′, C-3′, C-4′, C-5′). MS (MALDI): Calcd for
[C24H37N3O5SH]+: m/z 480.2532 [M]+; Found [M]+ 480.2531.
(3aR,3bS,6aS,7S,7aR)-1-Benzyl-7-bromo-5,5-dimethylhexahydro-1H[1,3]dioxolo[4′5′:3,4]
cyclopenta[1,2-c]isoxazole (25)
To an ice-cooled solution of alcohol 23 (ref. [57], 292 mg, 1.00 mmol) in dichloromethane (10 mL),
pyridine (0.324 mL, 4.01 mmol) and trifluoromethanesulfonyl anhydride (0.219 mL, 1.30 mmol) were
added and the reaction was allowed to reach ambient temp under stirring. After completed conversion
of the starting material, the reaction mixture was diluted with dichloromethane and consecutively
washed with aqueous HCl (6%) and saturated aqueous sodium bicarbonate. After drying (Na2SO4),
the filtrate was concentrated under reduced pressure. Resulting crude triflate 24 was dissolved in
DMF (10 mL) and NaBr (516 mg, 5.01 mmol) was added and the mixture was stirred at ambient
temp for 12 h. The reaction mixture was then concentrated under reduced pressure, the residue
was treated with CH2Cl2 and the resulting suspension was washed with brine. The organic layer
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was dried (Na2SO4), filtered and solvents were removed. Purification of the remaining residue on
silica gel (cyclohexane–EtOAc 10:1) provided bromodeoxy compound 25 (187 mg, 0.528 mmol, 53%,
over 2 steps) as a colorless syrup. [α]20D : +11.8 (c 1.0, CHCl3);
1H NMR (500 MHz, CDCl3); Mixture of
conformers: δ = 4.71–4.54 (m, 2 H, H-3, H-4), 4.30 (m, 1 H, J5,6a 4.2 Hz, J5,6a 8.5 Hz, H-6a), 4.08–4.01
(m, 2 H, H-6b, N-CH-Ph), 3.98 (dd, 1 H, J1,2 = J2,3 7.0 Hz, H-2), 3.91–3.75 (m, 2 H, H-1, N-CH-Ph),
3.38–3.28 (m, 1 H, H-5), 1.54, 1.32 (2 s, 3 H each, C(CH3)2). 13C NMR (125.9 MHz, CDCl3): δ = 113.5,
113.4 (C(CH3)2), 88.7, 88.2 (C-3), 79.4, 78.9 (C-1), 78.5, 78.1 (C-4), 65.0 (C-6), 59.8, 59.7 (N-CH2-Ph),
54.8 (C-2), 47.4, 47.1 (C-5), 27.5, 27.4, 25.6, 25.6 (C(CH3)2). MS (MALDI): Calcd for [C16H20BrNO3H]:
m/z 357.0705 [M]+; Found [M]+ 357.0708.
[(3aS,4R,5S,6aR)-5-Amino-2,3-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl]methanol (26)
A 10% methanolic solution of bromo compound 25 (187 mg, 0.528 mmol) was stirred with
Raney-Ni under an atmosphere of H2 at ambient pressure for 12 h. After completed conversion of the
starting material, the catalyst was removed by filtration, the filtrate was concentrated under reduced
pressure and the remaining residue was chromatographically purified (CHCl3–MeOH 8:1 + 1 vol% aq.
NH4OH (25%)) to provide aminocyclopentane 26 (65.4 mg, 0.349 mmol, 66%) as a pale yellow syrup.
[α]20D : −3.2 (c = 1.0, MeOH);
1H NMR (500 MHz, CD3OD) δ = 4.80 (dd, 1 H, J2,3 = J3,4 5.8 Hz, H-3),
4.73 (dd, 1 H, J4,5 5.7 Hz, H-4), 3.98 (dd, 1 H, J5,6a 7.0 Hz, J6a,6b 11.1 Hz, H-6a), 3.94 (dd, 1 H, J5,6b 8.1
Hz, H-6b), 3.39 (m, 1 H, H-1), 2.10–2.02 (m, 2 H, H-2a, H-5), 2.01 (ddd, 1 H, J2b,3 5.8 Hz, J2a,2b 11.8 Hz,
H-2b), 1.52, 1.37 (C(CH3)2. 13C NMR (125.9 MHz, CD3OD) δ = 110.8 (C(CH3)2), 82.4 (C-3), 82.3 (C-4),
59.0 (C-6), 56.0 (C-1), 51.2 (C-5), 40.7 (C-2), 26.9, 23.0 (C(CH3)2). MS (MALDI): Calcd for [C9H17NO3H]:
m/z 188.1287 [M+H]+; Found [M+H]+ 188.1287.
(1R,2S,3R,4S)-4-Amino-3-(hydroxymethyl)cyclopentane-1,2-diol (27)
A solution of isopropylidene acetal 26 (15.8 mg, 84.4 µmol) in methanol (0.5 mL) was treated
with aqueous HCl (2 M, 0.5 mL) at ambient temperature. After completed conversion was observed
solvents were removed under reduced pressure and the remaining residue was purified on silica gel
(CHCl3–MeOH–NH4OH (25%). 8:4:1) to give free polyol 27 as the free base (10.2 mg, 69.3 mmol, 82%).
[α]20D : +18.5 (c 0.86, H2O, pH 1);
1H NMR (500 MHz, CD3OD) δ = 4.15 (dd, 1 H, J2b,3 4.4 Hz, J3,4 3.9 Hz,
J2a,3 8.4 Hz, H-3), 4.08 (dd, 1 H, J4,5 3.8 Hz, H-4), 3.93 (dd, 1 H, J5,6a 7.3 Hz, J6a,6b 11.2 Hz, H-6a), 3.83 (dd,
1 H, J5,6b 7.8 Hz, H-6b), 3.61 (ddd, 1 H, J1,2a 8 Hz, J1,2b 4.4 Hz, J1,5 4 Hz, H-1), 2.59 (ddd, 1 H, J2a,3 8.3 Hz,
J2a,2b 14.3 Hz, J1,2a 8 Hz, H-2a), 2.20 (dddd, 1 H, H-5), 1.58 (ddd, 1 H, J1,2b 4.4 Hz, J2b,3 8 Hz, H-2b).
13C NMR (125.9 MHz, CD3OD) δ = 73.1 (C-4), 72.1 (C-3), 57.2 (C-6), 50.1 (C-1), 45.3 (C-5), 37.3 (C-2).
MS (MALDI): Calcd for [C9H17NO3H]: m/z 148.0974 [M + H]+; Found [M+H]+ 148.0976.
6-[(3aS,4R,5S,6aR)-4-Hydroxymethyl-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-5-yl)
amino]hexanoic nitrile (28)
Intermediate 26 (25.4 mg, 0.136 mmol) was dissolved in DMF (1 mL), 6-bromohexanoic nitrile
(23.4 µL, 0.176 mmol) and NaHCO3 (45.6 mg, 0.705 mmol) were added and the mixture was stirred at
60 ◦C until quantitative conversion of the starting material was observed. The solvent was removed
under reduced pressure and the remaining residue was purified by chromatography on silica gel
(CHCl3–MeOH 15:1 + 1 vol% NH4OH (25%)) to yield cyanopentylamine 28 (23.6 mg, 62%) as a faintly
yellow syrup. [α]20D : +18.1 (c 1.0, CHCl3);
1H-NMR (300 MHz, CDCl3): δ = 4.68 (dd, 1 H, J2,3 = J3,4
6 Hz, H-3), 4.57 (dd, 1 H, J4,5 6 Hz, H-4), 4.05 (dd, 1 H, J5,6a 7.7 Hz, J6a,6b 11.7 Hz, H-6a), 3.93 (dd, 1 H,
J5,6b 6.7 Hz, H-6b), 3.21 (dd, 1 H, J1,2b = J1,5 5.9 Hz, H-1), 2.85–2.70 (m, 2 H, H-1′a, NH), 2.43–2.26 (m,
3 H, H-1′b, H-5′), 2.23–2.01 (m, 2 H, H-2a, H-5), 1.73–1.38 (m, 8 H, H-2b, H-2′, H-3′, H-4′, 6-OH), 1.45,
1.28 (2 s, 3H each, C(CH3)2). 13C-NMR (75.5 MHz, CDCl3): δ = 119.7 (CN), 110.1 (C(CH3)2), 81.2, 81.1
(C-3, C-4), 61.3 (C-1), 59.7 (C-6), 47.8 (C-5), 47.4 (C-1′), 34.8 (C-2), 29.6, 26.8, 26.6, 25.4, 23,2, 17.2 (C-2′,
C-3′, C-4′, C-5′, C(CH3)2). MS (MALDI): Calcd for [C15H26N2O3H]: m/z 283.2022 [M + H]+; Found [M
+ H]+ 283.2020.
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(3aS,4R,5S,6aR)-5-(6-aminohexyl)amino-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]
dioxol-4-yl]methanol (29)
A 10% methanolic solution of nitrile 28 was stirred with Raney-Ni under an atmosphere of H2
at ambient pressure and temperature until completed consumption of the starting material (30 min).
The catalyst was then removed by filtration, the filtrate was concentrated under reduced pressure
and the remaining residue was chromatographed on silica gel (CHCl3–MeOH–NH4OH (25%) 8:4:1)
providing diamine 29 (18.5 mg, 78%) as a pale yellow syrup. [α]20D : −3.4 (c 0.82, MeOH);
1H-NMR
(300 MHz, CDCl3): δ = 4.68 (dd, 1 H, J2,3 = J3,4 6.0 Hz, H-3), 4.57 (dd, 1 H, J4,5 5.8 Hz, H-4), 4.05 (dd, 1 H,
J5,6a 7.6 Hz, J6a,6b 11.6 Hz, H-6a), 3.93 (dd, 1 H, J5,6b 6.4 Hz, H-6b), 3.22 (dd, 1 H, J1,2b = J1,5 6.0 Hz, H-1),
3.10 (bs, 3 H, 1-NH, 6′-NH2), 2.72 (m, 3 H, H-1′a, H-6′), 2.37 (m, 1 H, H-1′b), 2.22–2.01 (m, 2 H, H-2a,
H-5), 1.67–1.54 (m, 1 H, H-2b), 1.53–1.22 (m, 15 H, H-2′, H-3′, H-4′, H-5′, 6-OH, C(CH3)2). 13C-NMR
(75.5 MHz, CDCl3): δ = 110.1 (C(CH3)2), 81.3, 81.0 (C-3, C-4), 61.3 (C-1), 59.6 (C-6), 47.7, 47.6 (C-5, C-1′),
41.8 (C-6′), 34.9 (C-2), 32.6, 30.2, 27.2, 26.7, 26.7, 23.2 (C-2′, C-3′, C-4′, C-5′, C(CH3)2). MS (MALDI):
Calcd for [C15H30N2O3H]: m/z 287.2335 [M + H]+; Found [M + H]+ 287.2332.
(3aS,4R,5S,6aR)-2,2-Dimethyl-5-[6-(dansylamino)hexyl]aminotetrahydro-4H-cyclopenta[d][1,3]
dioxol-4-yl)methanol (30)
A solution of diamine 29 (18.2 mg, 63.5 µmol) in CH2Cl2–DMF (1 mL, 3:1) was treated with
trimethylamine (35.4 µL, 254 µmol) and dansyl chloride (18.9 mg, 69.9 µmol). After completed
conversion of the starting material (20 min), the solvents were removed under reduced pressure and
the residue was chromatographed on silica gel (CHCl3–MeOH 15:1 + 1 vol% NH4OH (25%)) furnishing
dansyl amide 30 (27.6 mg, 48.6 µmol, 84%) as a yellow syrup. [α]20D : −1.4 (c 1.1, MeOH);
1H-NMR
(300 MHz, CDCl3): δ = 4.98 (bs, 1 H, NH-dansyl), 4.67 (dd, 1 H, J2b,3 = J3,4 6.0 Hz, H-3), 4.56 (dd, 1 H,
J4,5 5.8 Hz, H-4), 4.05 (dd, 1 H, J5,6a 7.6 Hz, J6a,6b 11.4 Hz, H-6a), 3.94 (dd, 1 H, J5,6b 6.5 Hz, H-6b), 3.19 (m,
1 H, J1,2b = J1,5 5.8 Hz, H-1), 2.91–2.82 (m, 8 H, H-6′, dansyl), 2.70–2.59 (m, 1 H, H-1′a), 2.34–2.23 (m,
1 H, H-1′b), 2.19–1.98 (m, 2 H, H-2a, H-5), 1.60 (ddd, 1 H, J1,2b 14.9 Hz, H-2b), 1.43, 1.27 (2 s, 3H each,
C(CH3)2), 1.41–1.06 (m, 5 H, H-2′, H-3′, H-4′, H-5′). 13C-NMR (75.5 MHz, CDCl3): δ = 110.1 (C(CH3)2),
81.2, 81.0 (C-4, C-3), 61.4 (C-1), 59.7 (C-6), 47.5, 47.4 (C-5, C-1′), 45.5 (dansyl), 43.2 (C-6′), 34.9 (C-2), 29.8,
29.6, 26.7, 26.6, 26.1, 23.2 (C-2′, C-3′, C-4′, C-5′, C(CH3)2). MS (MALDI): Calcd for [C27H41N3O5SH]:
m/z 520.2845 [M + H]+; Found [M + H]+ 520.2848.
(1R,2S,3R,4S)-3-Hydroxymethyl-4-(6′-dansylaminohexylamino)cyclopentane-1,2-diol (31)
A solution of isopropylidene acetal 30 (27.4 mg, 527 µmol) in THF (0.5 mL) was treated with
aqueous HCl (1 M, 0.5 mL) at ambient temperature. Solvents were removed under reduced pressure
and the remaining residue was purified on silica gel (CHCl3–MeOH 8:1 + 1 vol% NH4OH (25%)) to
give free carbasugar 31 as the free base (18.5 mg, 38.6 µmol, 73%). [α]20D : +17.6 (c 0.80, MeOH, free base);
1H-NMR (300 MHz, CDCl3): δ = 4.04 (ddd, 1 H, J2a,3 7.9 Hz, J2b,3 = J3,4 4.3 Hz, H-3), 3.96 (dd, 1 H,
J4,5 4.4 Hz, H-4), 3.93–3.86 (m, 2 H, H-6a, H-6b), 3.39 (ddd, 1 H, J1,2b = J1,5 5.4 Hz, H-1), 2.93–2.80 (m,
8 H, H-6′, dansyl), 2.79–2.54 (m, 2 H, H-1′), 2.37 (ddd, 1 H, J1,2a = J2a,3 7.9 Hz, J2a,2b 14.2 Hz, H-2a),
2.23 (dddd, 1 H, J5,6a = J5,6b 7 Hz, H-5), 1.69 (m, 1 H, H-2b), 1.49–1.04 (m, 8 H, H-2′, H-3′, H-4′, H-5′).
13C-NMR (75.5 MHz, CDCl3): δ = 74.5 (C-4), 73.2 (C-3), 58.8 (C-6), 58.6 (C-1), 48.4 (C-1′), 47.0 (C-5),
45.8 (dansyl), 43.7 (C-6′), 37.4 (C-2), 30.4, 28.4, 27.3, 27.1 (C-2′, C-3′, C-4′, C-5′). MS (MALDI): Calcd for
[C24H37N3O5SH]: m/z 480.2532 [M + H]+; Found [M + H]+ 480.2533.
(3aR,3bS,6aS,7S,7aR)-1-Benzyl-7-fluoro-5,5-dimethylhexahydro-1H-[1,3]dioxolo[4′,5′:3,4]
cyclopenta[1,2-c]isoxazole (32)
A solution of alcohol 23 (ref. [57], 298 mg, 1.02 mmol) in CH2Cl2 (10 mL) was cooled to 0 ◦C
and treated with pyridine (0.330 mL, 4.09 mmol) and DAST (0.270 mL, 2.05 mmol). When completed
conversion of the starting material was observed (2 h), the reaction mixture was quenched with
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saturated aqueous NaHCO3 and the organic layer was dried with Na2SO4, filtered and the solvent was
removed under reduced pressure. Purification of the residue on silica gel (cyclohexane-EtOAc 10:1)
provided deoxyfluoro compound 32 (245 mg, 0.835 mmol, 82%). [α]20D : +55.5 (c 1.6, CHCl3);
1H NMR
(500 MHz, CDCl3): δ = 4.78 (m, 1 H, J2,F 50.7 Hz, H-2), 4.60 (m, 1 H, H-4), 4.58 (m, 1 H, J3,F 19 Hz, J2,3
6.5 Hz, J3,4 3.7 Hz, H-3), 4.20 (dd, 1 H, J5,6a 3.7 Hz, J6a,6b 8.6 Hz, H-6a), 3.98–3.89 (m, 2 H, J5,6b 8.5 Hz,
H-6b, N-CH-Ph), 3.76 (d, 1H, N-CH-Ph) 3.71 (m, 1 H, J1,F 20 Hz, J1,2 = J1,5 4 Hz, H-1), 3.30 (m, 1 H, H-5),
1.46, 1.24 (2 s, 3 H each, C(CH3)2). 13C NMR (75.5 MHz, CDCl3): δ = 113.0 (C(CH3)2), 100.3 (J2,F 182 Hz,
C-2), 85.3 (J2,F 27.9 Hz, C-3), 77.7 (J4,F 4.7 Hz, C-4), 75.9 (J1,F 25.1 Hz, C-1), 65.0 (C-6), 59.8 (N-CH2-Ph),
47.5, (J5,F 3.5 Hz, C-5), 26.9, 25.3 (C(CH3)2). 19F NMR (470.3 MHz, CDCl3): δ = −189.4. MS (MALDI):
Calcd for [C16H20FNO3H]: m/z 294.1505 [M + H]+; Found [M + H]+ 294.1504.
[(3aS,4R,5R,6S,6aS)-5-Amino-6-fluoro-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl]
methanol (33)
A methanolic solution (3%) of isoxazolidine 32 (348 mg, 1.18 mmol) was stirred with Pearlman’s
catalyst (Pd(OH)2/C, 20%) under an atmosphere of H2 at ambient pressure for 1 h. After completed
conversion, the suspension was filtered, the filtrate was concentrated under reduced pressure and the
residue was chromatographically purified (CHCl3–MeOH 14:1 + 1 vol% NH4OH (25%)) to obtain 33
as a pale yellow syrup (238 mg, 1.16 mmol, 98 %). [α]20D : +22.5 (c 0.70, CHCl3);
1H NMR (500 MHz,
CDCl3): δ = 4.73 (dd, 1 H, J3,4 = J4,5 5.4 Hz, H-2), 4.72 (bd, 1 H, J2,F 48 Hz, H-2), 4.60 (ddd, 1 H,
J3,F 16.6 Hz, J2,3 5.8 Hz, H-3), 4.01 (dd, 1 H, J5,6a 7.7 Hz, J6a,6b 11.3 Hz, H-6a), 3.95 (dd, 1 H, J5,6b 6.8 Hz,
H-6b), 3.47 (dd, 1 H, J1,F 14.4 Hz, J1,5 6.3 Hz, H-1), 2.44 (ddd, 1 H, H-5), 2.07 (bs, 3 H, 6-OH, 1-NH2),
1.45, 1.29 (2 s, 3 H each, C(CH3)2). 13C NMR (75.5 MHz, CDCl3): δ = 111.3 (C(CH3)2), 100.5 (J2,F
180.5 Hz, C-2), 84.1 (J3,F 33.7 Hz, C-3), 80.9 (C-4), 58.1 (J1,F 22.4 Hz, C-1), 58.0 (C-6), 46.4, (C-5), 26.3,
25.0 (C(CH3)2). 19F NMR (470.3 MHz, CDCl3): δ = −181.1. MS (MALDI): Calcd for [C9H16NO3H]:
m/z 206.1192 [M + H]+; Found [M + H]+ 206.1192.
(1S,2S,3S,4R,5R)-4-Amino-3-fluoro-5-hydroxymethylcyclopentane-1,2-diol (34)
A 10% methanolic solution of compound 33 (238 mg, 1.16 mmol) was treated with HCl (12 M,
0.1 mL) for 2 h. After completed conversion of the starting material, the solution was concentrated
under reduced pressure and the residue was chromatographically purified (CHCl3–MeOH–NH4OH
(25%) 8:4:1) to obtain free compound 34 (177 mg, 1.07 mmol, 92 %) as a colorless syrup. Treatment
with HClg in methanol in the presence of small amounts of ethyl acetate afforded the corresponding
hydrochloride (34·HCl) as a white solid. [α]20D : +31.2 (free base, c 0.88, H2O);
1H NMR (500 MHz, D2O)
(free base): δ = 5.17 (ddd, 1 H, J2,F 52.5 Hz, J1,2 3.9 Hz, J2,3 7.0 Hz, H-2), 4.32 (dd, 1 H, J3,F = 21.7 Hz,
J3,4 3.9 Hz, H-3), 4.27 (dd, 1 H, J4,5 4 Hz, H-4), 4.01 (ddd, 1 H, J1,F 20.8 Hz, J1,5 8.8 Hz, H-1), 3.99 (dd,
1 H, J5,6a 6.6 Hz, J6a,6b 11.7 Hz, H-6a), 3.91 (dd, 1 H, J5,6b 8.0 Hz, H-6b), 2.79 (dddd, 1 H, H-5). 13C NMR
(75.5 MHz, D2O) (free base): δ= 101.6 (J2,F 185.9 Hz, C-2), 76.1 (J3,F 22.0 Hz, C-3), 72.2 (J4,F 9.1 Hz,
C-4), 56.6 (C-6), 54.4 (J1,F 26.8 Hz, C-1), 41.8, (J5,F 2.7 Hz, C-5). 19F NMR (470.3 MHz, D2O) (free base):
δ = −192.4. 1H NMR (300 MHz, D2O) (hydrochloride): δ = 5.12 (ddd, 1 H, J2,F 52.3 Hz, J1,2 3.9 Hz, J2,3
6.6 Hz, H-2), 4.26 (dd, 1 H, J3,F = 21.3 Hz, J3,4 4.1 Hz, H-3), 4.20 (dd, 1 H, J4,5 3.8 Hz, H-4), 3.97 (ddd, 1 H,
J1,F 20.9 Hz, J1,5 8.8 Hz, H-1), 3.92 (dd, 1 H, J5,6a 6.9 Hz, J6a,6b 11.5 Hz, H-6a), 3.83 (dd, 1 H, J5,6b 8.2 Hz,
H-6b), 2.74 (dddd, 1 H, H-5). 13C NMR (75.5 MHz, D2O) (hydrochloride): δ = 100.9 (J2,F 186.3 Hz, C-2),
76.1 (J3,F 22.0 Hz, C-3), 72.1 (J4,F 9.1 Hz, C-4), 56.5 (C-6), 54.4 (J1,F 27.3 Hz, C-1), 41.5, (J5,F 2.5 Hz, C-5).
MS (MALDI): Calcd for [C6H12FNO3H]: m/z 166.0880 [M + H]+; Found [M + H]+ 166.0883.
Benzyl 6-(1R,2S,3S,4S,5R)-2-fluoro-3,4-dihydroxy-5-(hydroxymethyl)cyclopentylamino
hexylcarbamate (35)
To a 10% solution of amine 34 (117 mg, 0.708 mmol) and acetic acid (40 µL), benzyl (6-oxohexyl)
carbamate [68] (230 mg, 0.921 mmol) was added. After 5 min, sodium cyanoborohydrate (66.8 mg,
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1.06 mmol) was added and the suspension was stirred until completed conversion was observed
(1 h). The solvent was removed under reduced pressure and the residue was chromatographically
purified (CHCl3–MeOH 8:1 + 1 vol% NH4OH (25%)) to obtain compound 35 as a colorless syrup
(169 mg, 0.424 mmol, 60%). [α]20D : +16.8 (c 1.1, MeOH);
1H NMR (500 MHz, CD3OD): δ = 5.13 (s, 2 H,
NH(C-O)-O-CH2-Ph), 4.85 (ddd, 1 H, J2,F 53.4 Hz, J1,2 = J2,3 4.6 Hz, H-2), 4.12 (dd, 1 H, J3,4 = J3,4 4.4 Hz,
H-4), 4.05 (ddd, 1 H, J3,F 22.2 Hz, H-3), 3.94 (dd, 1 H, J5,6a 6.8 Hz, J6a,6b 11.4 Hz, H-6a), 3.84 (dd, 1 H,
J5,6b 6.6 Hz, H-6b), 3.24 (ddd, 1 H, J1,F 21.8 Hz, J1,5 8.4 Hz, H-1), 3.18 (t, 2 H, J 6.9 Hz, H-6′), 2.81 (m, 1 H,
H-1′a), 2.60 (m, 1 H, H-1′b), 2.46 (m, 1 H, H-5), 1.63–1.34 (m, 8 H, H-2′, H-3′, H-4′, H-5′). 13C NMR
(75.5 MHz, CD3OD) (free base): δ = 158.9 (NH(C-O)-O-CH2-Ph), 106.0 (J2,F 185.0 Hz, C-2), 78.5 (J3,F
23.1 Hz, C-3), 73.6 (J4,F 8.3 Hz, C-4), 67.3 (N(C-O)-O-CH2-Ph), 63.2 (J1,F 22.4 Hz, C-1), 58.7 (C-6), 45.9,
(J5,F 3.8 Hz, C-5), 41.7 (C-6′), 30.8, 30.5, 28.0, 27.6 (C-2′, C-3′, C-4′, C-5′). 19F NMR (470.3 MHz, CD3OD):
δ = −184.3. MS (MALDI): Calcd for [C6H12FNO3H]: m/z 399.2295 [M+H]+; Found [M+H]+ 399.2295.
(1S,2S,3S,4R,5R)-4-(6′-Dansylaminohexyl)amino-3-fluoro-5-hydroxymethylcyclopentane-1,2-
diol (37)
To a solution of carbamate 35 (52.5 mg, 0.132 mmol) in MeOH, 10% Pd/C was added and the
suspension was stirred under an atmosphere of H2 at ambient pressure. After completed conversion
was observed (1 h), the suspension was filtered and the filtrate was concentrated under reduced
pressure. The residue of crude free amine 36 was dissolved in CH3CN/H2O (1 mL, 5:1) and treated with
Et3N (55.1 µL, 0.395 mmol) and dansyl chloride (39.1 mg, 0.145 mmol). After completed conversion of
the starting material (20 min), the solvent was removed under reduced pressure. Purification on silica
gel (CHCl3–MeOH. 8:1 + 1 vol% NH4OH (25%)) provided compound 37 (38.2 mg, 69.2 µmol, 53%,
over 2 steps) as yellow syrup. [α]20D : +14.0 (c 1.8, MeOH);
1H NMR (500 MHz, CD3OD): δ = 4.83 (ddd,
1 H, J2,F 53.4 Hz, J1,2 4.0 Hz, J2,3 4.4 Hz, H-2), 4.12 (dd, 1 H, J3,4 = J3,4 4.6 Hz, H-4), 4.05 (ddd, 1 H, J3,F
22.2 Hz, H-3), 3.92 (dd, 1 H, J5,6a 6.8 Hz, J6a,6b 11.2 Hz, H-6a), 3.82 (dd, 1 H, J5,6b 6.5 Hz, H-6b), 3.20 (ddd,
1 H, J1,F 21.7 Hz, J1,5 8.3 Hz, H-1), 2.96–2.88 (m, 8 H, H-6′, dansyl), 2.67 (m, 1 H, H-1′a), 2.49–2.41 (m,
2 H, H-5, H-1′b), 1.42–1.06 (m, 8 H, H-2′, H-3′, H-4′, H-5′). 13C NMR (75.5 MHz, CD3OD): δ = 105.6
(J2,F 185.1 Hz, C-2), 78.5 (J3,F 23.1 Hz, C-3), 73.6 (J4,F 8.3 Hz, C-4), 63.2 (J1,F 22.4 Hz, C-1), 58.7 (C-6),
48.6 (C-1′), 45.9, (J5,F 4.1 Hz, C-5), 45.8 (dansyl), 43.7 (C-6′), 30.4, 30.3, 27.7, 27.3 (C-2′, C-3′, C-4′, C-5′).
19F NMR (470.3 MHz, CD3OD): δ = −184.4. MS (MALDI): Calcd for [C6H12FNO3H]: m/z 498.2438
[M+H]+; Found [M+H]+ 498.2439.
4.2. Kinetic Studies
Kinetic studies were performed at 37 ◦C in an appropriate buffer (specific conditions depicted
below). In a typical assay, the enzyme was incubated with different inhibitor concentrations for
up to 5 min before initiating the reaction by the addition of substrate. The initial reaction rate was
measured by monitoring the increase in absorbance at 400 nm for up to ten minutes using a Cary4000
(Varian, Palo Alto, CA, USA). Ki determinations were performed using at least two different substrate
concentrations. For each inhibitor, a range of four to six inhibitor concentrations bracketing the
ultimately determined Ki value was used for each substrate concentration. Dixon plots (1/v vs. [I])
were constructed to validate the use of competitive inhibition model. The data were then fit using
non-linear regression analysis with Grafit 7.0 [Erithacus Software, UK].
n.i. stands for no inhibition or weak inhibition with an estimated Ki value higher than 1 mM.
Specific Assay Conditions for Each Enzyme
Agrobacterium sp. β-glucosidase: [69,70] 50 mM sodium phosphate buffer (pH 7). Substrate:
pNP β-Gal, Km = 4.1 mM.
E. coli lac z β-galactosidase: 50 mM sodium phosphate, 1.0 mM MgCl2 (pH 7). Substrate:
pNP β-Gal, Km = 60 µM.
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Bovine liver β-galactosidase: 50 mM sodium phosphate buffer (pH 7). Substrate: pNP β-Gal,
Km = 0.65 mM.
Fabrazyme (Acid α-galactosidase): 20 mM sodium citrate, 50 mM sodium phosphate, 1.0 mM
tetrasodium EDTA, 0.25% v/v Triton X-100® and 0.25% w/v taurocholic acid buffer (pH 5.5). Substrate:
2,4-DNP α-Gal [71], Km = 0.65 mM.
GCase (β-glucocerebrosidase): 20 mM sodium citrate, 50 mM sodium phosphate, 1.0 mM
tetrasodium EDTA, 0.25% v/v Triton X-100® and 0.25% w/v taurocholic acid buffer (pH 7). Substrate:
2,4-DNP β-Glc [71], Km = 2.7 mM.
S. cerevisiae α-Glucosidase: 50 mM sodium phosphate buffer (pH 7.0). Substrate: pNP α-Glc,
Km = 0.75 mM.
Human β-galactosidase and β-hexosaminidase activity measurements were performed in
duplicate assays, unless otherwise stated. Fibroblast cells were harvested by trypsinization in
0.9% NaCl containing 0.01% Triton, homogenized by sonication (3 × 10 s, Sonifier Bandelin Sonopuls,
Bandelin, Berlin, Germany) and centrifuged at 13,000 rpm for 2 min in a table top centrifuge (Biofuge
Pico, Heraeus, Hanau, Germany). Protein amounts were determined according to the method of
Lowry [72].
For assessment of β-Gal activity, 20 µL of cell homogenate were mixed with 100 µL of 0.5 mM
4-methylumbelliferyl-β-d-galactopyranoside (Sigma-Aldrich, St. Louis, MO, USA), in 100 mM citrate
buffer (pH 4.0) containing 100 mM NaCl and 0.02% NaN3. After incubation at 37 ◦C for 30 min,
the reaction was stopped by adding 2.5 mL 400 mM glycine/NaOH (pH 10.4).
β-Hexosaminidase activity was measured by adding 10 µL homogenate to 90 µL 0.9% NaCl and
100µL of 1 mM 4-methylumbelliferyl-N-acetyl-β-d-glucosaminide (Sigma-Aldrich, St. Louis, MO, USA)
in 100 mM citrate buffer (pH 4.6) containing 0.2% BSA and 0.04% NaN3. The reaction was stopped after
10 min at 37 ◦C by addition of 2.5 mL of 400 mM glycine/NaOH (pH 10.4). The amount of hydrolyzed
4-methylumbelliferone was determined with a fluorescence spectrometer Hitachi F7000 (Chiyoda,
Japan). All compounds probed were found practically devoid of β-hexosaminidase inhibitory activity.
Modified β-Gal assays were used to estimate the half maximal inhibitory concentration (IC50) of
the particular chaperone. For IC50 determination, 0.001 to 100 µM of chaperone was added to the assay
mixture. Activity was measured in normal fibroblasts. Data analysis was performed with Microcal™
Origin® v6.0 (Origin Lab, Northampton, MA, USA) using a non-linear curve fitting module based on
sigmoid curve fitting.
4.3. CjGH35 Purification and Crystallisation
CjGH35 was expressed and purified as in Larsbrink [73]. Crystals were grown by Sitting Drop
Vapour Diffusion using protein at 25–36 mg/mL in 25 mM HEPES pH 7.0, 100 mM NaCl, in ratios of
0.8–1.2 µL to 1 µL well solution, with the latter comprised of 2.3–2.8 M sodium acetate pH 7.4–7.6.
Crystals were soaked with a speck of solid ligand powder, introduced into the drop on the end
of a needle, for 1 to 3 days, and frozen directly into liquid nitrogen using Hampton CryoLoopsTM
(Hampton, CA, USA).
4.4. Data Collection and Structure Refinement
Data were collected at the Diamond Light Source on beamlines IO4 (1, 16 and 17), IO4-1 (31) and
IO2 (14 and 22), and processed using DIALS (1, 16, 17, 22 and 31) [74] or XDS (14) [75]. All data were
scaled with AIMLESS [76] to resolutions of 1.46 to 1.60 Å, and were in space group P1. The structures
were solved by molecular replacement using REFMAC (for 1, 16, 17 and 22) [77] or PHASER (31 and
14) [78] using the structure of 4D1I.pdb without water molecules and ions as the model. The datasets
were in space group P1, with 8 molecules in the asymmetric unit. The structures were refined using
REFMAC, with twin refinement using observed intensities converted to amplitudes employed in the
case of 14, and anisotropic B-factor refinement employed for all of the structures. Manual rebuilding
was performed using Coot [79] followed by cycles of refinement, and the ligand molecules were added
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into 2mFo-DFc density maps calculated after the protein chains had been modelled and most of the
water molecules and sodium ions added. The crystallographic programs were run within the CCP4I2
suite [80].
4.5. Patients and Cell Lines
Cell lines from one GM1-Gangliosidosis-patient (R201C) and one WT, were exposed to compounds
22, 31, and 37, for evaluation of their chaperone effects.
Human skin fibroblasts were grown in minimal essential medium (MEM) with Earle’s Salts
(Sigma Aldrich, St. Louis, MO, USA) containing 10% fetal bovine serum, 400 µM l-glutamine,
and 50 µg/mL gentamycin at 37 ◦C and 5% CO2. All cells used in this study were between the third
and nineteenth passages.
Potential chaperones were dissolved in DMSO and diluted in 10 mM phosphate buffer (pH 7.0)
containing 100 mM NaCl, 0.01% NaN3, and 0.01% Triton for the IC50-measurements and in MEM for
the in-vivo tests. The total DMSO concentration in the media was less than 1% and had no effect on
β-Gal activity or cell viability.
4.6. Treatment of Cultured Fibroblasts
Fibroblasts were grown to semi-confluency in 6-well plates. Particular chaperone was added
to the culture medium at following concentrations: 100–0.02 µmol. Cells were incubated for four
additional days at 37 ◦C. Cells were harvested by scraping and prepared for β-galactosidase and
β-hexosaminidase assays as described above.
Supplementary Materials: The following are available online at. XRD data and NMR spectra for new compounds.
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